Nebulizer maker HCmed Innovations and Cellics Therapeutics have agreed to collaborate on inhaled delivery of cellular nanosponges as antibacterial and anti-inflammatory therapies. Cellics is currently developing nanosponges based on red blood cells and macrophages, and the company expects to advance its CTI-005 RBC nanosponge into clinical development for the treatment of pneumonia caused by MRSA by the end of 2021.
HCmed will adapt its existing nebulizer technology specifically for delivery of the nanosponges. The company makes handheld breath-actuated vibrating mesh nebulizers, including the Pulmogine nebulizer, which was introduced in 2019. The Pulmogine device is customizable for delivery of a range of products, including biologics, and recently received 510(k) clearance from the FDA.
HCmed CEO Jason Cheng commented, “We are thrilled to be partnering with Cellics to provide support in bringing potential therapies to the market. HCmed is committed to continue contributing to the improvement of patients’ quality of life using our nebulizers. We look forward to working with Cellics to propel this project to the next stage.”
Cellics President Steve Chen said, “We believe that inhaled nanosponges will be able to be used in the treatment of several lung diseases, offering therapeutic benefits to patients.”
Read the HCmed press release.
